Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer
Authors
Keywords
-
Journal
Nature Communications
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-04-12
DOI
10.1038/s41467-023-37636-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Association Between Antibiotic Use and Outcome Among Metastatic Melanoma Patients Receiving Immunotherapy
- (2022) Florence Poizeau et al. JNCI-Journal of the National Cancer Institute
- Immunotherapy in triple-negative breast cancer: A literature review and new advances
- (2022) Guillermo Arturo Valencia et al. World Journal of Clinical Oncology
- Antibiotic exposure within six months before systemic therapy was associated with lower cancer survival
- (2022) Stephen Morrell et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
- (2021) Diwakar Davar et al. SCIENCE
- The microbiome and human cancer
- (2021) Gregory D. Sepich-Poore et al. SCIENCE
- Antibiotics Use and Subsequent Risk of Colorectal Cancer: A Swedish Nationwide Population-Based Study
- (2021) Sai San Moon Lu et al. JNCI-Journal of the National Cancer Institute
- Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth
- (2021) Alastair M. McKee et al. iScience
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression
- (2020) Lishay Parhi et al. Nature Communications
- Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
- (2020) Erez N. Baruch et al. SCIENCE
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Modulating the microbiome to improve therapeutic response in cancer
- (2019) Jennifer L McQuade et al. LANCET ONCOLOGY
- Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
- (2019) David J. Pinato et al. JAMA Oncology
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
- (2018) L Derosa et al. ANNALS OF ONCOLOGY
- Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer
- (2018) Anosheh Afghahi et al. CLINICAL CANCER RESEARCH
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Disruption of the Gut Ecosystem by Antibiotics
- (2018) Mi Young Yoon et al. YONSEI MEDICAL JOURNAL
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Marginal structural models in clinical research: when and how to use them?
- (2017) Tyler Williamson et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- The genomic landscape of breast cancer and its interaction with host immunity
- (2016) Stephen Luen et al. BREAST
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
- (2015) Melinda L. Telli et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical relevance of host immunity in breast cancer: from TILs to the clinic
- (2015) Peter Savas et al. Nature Reviews Clinical Oncology
- Age at diagnosis in relation to survival following breast cancer: a cohort study
- (2015) Jasmine Brandt et al. World Journal of Surgical Oncology
- Use of and Mortality After Bilateral Mastectomy Compared With Other Surgical Treatments for Breast Cancer in California, 1998-2011
- (2014) Allison W. Kurian et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast cancer treatment across health care systems: Linking electronic medical records and state registry data to enable outcomes research
- (2013) Allison W. Kurian et al. CANCER
- The California Breast Cancer Survivorship Consortium (CBCSC): prognostic factors associated with racial/ethnic differences in breast cancer survival
- (2013) Anna H. Wu et al. CANCER CAUSES & CONTROL
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
- (2013) N. Iida et al. SCIENCE
- The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
- (2013) S. Viaud et al. SCIENCE
- Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects
- (2013) John Stagg et al. Therapeutic Advances in Medical Oncology
- Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy
- (2011) Maria Angeles Vicente Conesa et al. BREAST
- Triple-Negative Breast Cancer: An Unmet Medical Need
- (2011) C. A. Hudis et al. ONCOLOGIST
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Constructing Inverse Probability Weights for Marginal Structural Models
- (2008) S. R. Cole et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Lymphopenia Associated with Adjuvant Anthracycline/Taxane Regimens
- (2008) Sara M. Tolaney et al. Clinical Breast Cancer
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started